TABLE 1.
Patient characteristics at baseline (n = 80)a
| Parameter | No (%) of patients or median (IQR) |
|
|---|---|---|
| Amikacin | Kanamycinb | |
| General characteristics | ||
| Male (%) | 26 (48.1) | 17 (65.4) |
| Female (%) | 28 (51.9) | 9 (34.6) |
| Age (yr) | 30 (25–39) | 31 (25–40) |
| Wt (kg) | 61.4 (55.2–68.4) | 57.2 (50.0–68.2) |
| BMI (kg/m2) | 21.2 (19.4–23.6) | 20.5 (18.5–22.4) |
| Ethnicity (%) | ||
| European | 7 (13.0) | 2 (7.7) |
| Asian | 17 (31.5) | 4 (15.4) |
| African | 14 (25.9) | 12 (46.2) |
| Other | 14 (25.9) | 7 (26.9) |
| Unknown | 2 (3.7) | 1 (3.8) |
| Tuberculosis | ||
| Localization (%) | ||
| Pulmonary | 42 (77.8) | 19 (73.1) |
| Extrapulmonary | 6 (11.1) | 3 (11.5) |
| Both pulmonary and extrapulmonary | 6 (11.1) | 4 (15.4) |
| Drug susceptibility | ||
| MDR (%) | 52 (96.3) | 26 (100) |
| XDR (%) | 2 (3.7) | 0 |
| Comorbidity | ||
| Diabetes mellitus type 1 (%) | 3 (5.6) | 1 (3.8) |
| Diabetes mellitus type 2 (%) | 3 (5.6) | 1 (3.8) |
| HIV coinfection (%) | 4 (7.4) | 4 (15.4) |
| Creatinine level at baseline | 64.0 (50.8–77.3) | 69.5 (51.3–77.3) |
a
The results are presented as median with interquartile range (IQR) in parentheses or as the number (%) of patients. BMI, body mass index; MDR, multidrug resistant; XDR, extensively drug resistant; HIV, human immunodeficiency virus.
b
One patient used amikacin but switched to kanamycin. This patient was included in the kanamycin results, since this aminoglycoside treatment represented the largest treatment period.